Evaluation of efficacy and safety of gefitinib as monotherapy in Chinese patients with advanced non-small cell lung cancer and very poor performance status

BACKGROUND: This paper reports the outcome of gefitinib for Chinese advanced NSCLC patients with poor performance status (PS) at the Peking Union Medical College Hospital. METHODS: From Oct 2002 to Apr. 2006, 42 advanced NSCLC patients with PS 3/4 received gefitinib 250 mg/day treatment. Median surv...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Zhong, Mengzhao, Wang, Li, Zhang, Longyun, Li, Xiaotong, Zhang
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2588452/
https://www.ncbi.nlm.nih.gov/pubmed/18957121
http://dx.doi.org/10.1186/1756-0500-1-102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2588452/
https://www.ncbi.nlm.nih.gov/pubmed/18957121
http://dx.doi.org/10.1186/1756-0500-1-102

Ejemplares similares